At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
GVAX pancreas vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety and Efficacy Trial of Vaccine Boosting With Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Oct 19, 2006·Updated Oct 26, 2023
In Brief
A Phase 2 clinical trial evaluating GVAX pancreas vaccine for Pancreatic Cancer. Completed, enrolled 56 participants across 1 site.
Detailed Summary
This is an open label, phase II trial study of adjuvant GVAX pancreas vaccine in patients with pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
CollaboratorsThe Skip Viragh Foundation, National Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
First PostedOct 2006
Primary CompletionOct 2021
Study CompletionDec 2022
TodayJul 2026
First PostedOct 19, 2006
Enrollment StartSep 11, 2006
Primary CompletionOct 11, 2021
Study CompletionDec 10, 2022
TodayJul 2, 2026
Enrollment to primary: 15.1 yearsPosted 19.7 years ago
Interventions
GVAX pancreas vaccinebiological
Given intradermally